Recurrent Head and Neck Squamous Cell Carcinoma Not Yet Recruiting Phase 2 Trials for Cemiplimab (DB14707)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04862650Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckTreatment